The prime objective of the Boston University Alzheimer's Disease Center (BU ADC) is to provide resources to support high impact studies on the pathogenesis, detection, and treatment of Alzheimer's Disease (AD) and related disorders. The leadership team and investigators affiliated with the BU ADC represent a dynamic forward thinking team of clinicians and scientists who have made significant contributions to AD-related research and are committed to advancing the field in the years ahead. The BU ADC consists of an Administrative Core, Clinical Core, Data Management and Statistics Core, Neuropathology Core, Education and Information Transfer Core, and a Translational and Transgenic Core. The BU ADC has four aims.
Aim 1 is to foster and support high-impact, innovative, state of the art research on brain aging and AD by: a) identifying, recruiting, and thoroughly characterizing subjects willing to participate in clinical trials and other cutting-edge clinical research studies; b) collecting, storing, analyzing, and distribute biological samples to support high priority AD-related research; c) conducting state-of the-art diagnostic neuropathological evaluation and maximize CNS tissue donation to support state of the art tissue-based research; and d) fostering innovative AD research through a strong pilot project program.
Aim 2 is to collect and submit high quality data to the Data Management and Statistics Core for timely UDS submissions to the NACC database and for data sharing with qualified AD investigators engaged in cutting edge AD-related research while ensuring data security and integrity.
Aim 3 is to support and inform the communities we serve regarding the benefits of the BU ADC and AD research and to provide a high-quality training environment for professionals at all career levels. The BU ADC has developed innovative approaches to educate medical students about AD and has pioneered methods to increase African American brain donation.
Aim 4 is to breed and disseminate transgenic mouse models of AD and related disorders and to provide specialized technical services to support cutting edge translational AD-related research.

Public Health Relevance

Alzheimer's disease (AD) affects over 5 million people and is the 7th leading cause of death in the USA. Despite advances in understanding of how AD and other age-related diseases cause loss of brain function, much more research is needed on how AD and related disorders develop, how to detect them at their earliest stages, and how to treat them effectively once they develop. The mission of the Boston University Alzheimer's Disease Center is to provide resources to accelerate research addressing these vital questions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG013846-20
Application #
8870239
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Silverberg, Nina B
Project Start
1997-07-15
Project End
2016-06-30
Budget Start
2015-07-15
Budget End
2016-06-30
Support Year
20
Fiscal Year
2015
Total Cost
$1,116,402
Indirect Cost
$230,368
Name
Boston University
Department
Neurology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Chung, Jaeyoon; Zhang, Xiaoling; Allen, Mariet et al. (2018) Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer's disease. Alzheimers Res Ther 10:22
Farrar, Danielle C; Mian, Asim Z; Budson, Andrew E et al. (2018) Retained executive abilities in mild cognitive impairment are associated with increased white matter network connectivity. Eur Radiol 28:340-347
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Bis, Joshua C; Jian, Xueqiu; Kunkle, Brian W et al. (2018) Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. Mol Psychiatry :
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17

Showing the most recent 10 out of 791 publications